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Introduction
Human blood pressure undergoes daily oscillations: blood pres-
sure is lowest at night (nocturnal dip) and rises before awaken-
ing (morning surge) (1). Such blood pressure circadian rhythm is 
critical to human health, as a 40% higher risk of acute myocardial 
infarction, a 29% higher risk of sudden cardiac death, and a 49% 
higher risk of stroke occur during the early morning blood pressure 
surge compared with the rest of the day (2, 3). It was long believed 
that blood pressure circadian rhythm, just like other physiological 
and behavioral circadian rhythms, was mostly controlled by the 
suprachiasmatic nucleus (SCN). However, this dogma was chal-
lenged by the discoveries that each of the core clock genes that 
exists in the SCN also expresses and functions in peripheral tis-
sues (4–7). These discoveries raise some fundamental questions: 
do these peripheral clock genes participate in the regulation of 
blood pressure circadian rhythm? And if so, which specific clock 
genes in which peripheral tissue or tissues are important for blood 
pressure circadian rhythm?
Smooth muscle is a major component of the blood vessel wall, 
and its primary physiological function is to maintain adequate 
organ blood supply and blood pressure homeostasis by adjusting 
its contractile state in response to environmental cues (8). Smooth-
muscle contractility exhibits time-of-day variation (9–14). Howev-
er, whether and how such time-of-day smooth-muscle contractile 
variation relates to blood pressure circadian rhythm are unknown. 
Moreover, the molecular mechanism that underlies time-of-day 
smooth-muscle contractile variation is unknown.
Aryl hydrocarbon receptor nuclear translocator–like (BMAL1), 
also known as Arntl3 in mouse and MOP3 in humans, is a central 
element of the core clock genes in mammals. Global Bmal1 dele-
tion in mice causes immediate and complete loss of rhythmicity, 
including in blood pressure circadian rhythm (15, 16). BMAL1 is 
expressed ubiquitously but functions in a tissue-specific man-
ner. For instance, it has been shown that brain-specific BMAL1 
expression in global Bmal1-knockout mice selectively restored 
wheel-running circadian rhythm, and skeletal muscle–specific 
BMAL1 expression selectively restored wheel-running level and 
body weight (17). However, the physiological function of BMAL1 
in smooth muscle and its contribution to blood pressure circa-
dian rhythm remain to be defined. The current study developed 
a smooth-muscle-specific Bmal1-knockout mouse model and 
demonstrated in vitro and in vivo that smooth-muscle BMAL1 is 
essential for normal vascular smooth-muscle contraction ampli-
tude and time-of-day variations as well as blood pressure level 
and circadian rhythm.
Results
Generation and characterization of a smooth-muscle–specific Bmal1-
knockout mouse model. We generated a smooth-muscle–specific 
Bmal1-knockout mouse model (SM-Bmal1–KO) by crossing 
Bmal1flox/flox mice (18) with smooth-muscle–specific SM22α-Cre 
mice (19). SM-Bmal1–KO mice were viable, fertile, and grossly 
normal. Four distinct approaches were taken to characterize 
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in the second branch of mesenteric arteries between SM-Bmal1–KO 
mice and WT littermates (Supplemental Figure 1, A and B; supple-
mental material available online with this article; doi:10.1172/
JCI76881DS1). These data suggest that smooth-muscle Bmal1 dele-
tion has little effect on vascular structure and, thus, that the sup-
pression of contraction amplitude in tissues from SM-Bmal1–KO 
mice is unlikely to be attributed to vascular structure changes.
We also determined the contractile responses to K+, PE, and 
5-HT in right renal arteries and found suppression in contractile 
time-of-day variation and amplitude similar to that found in mes-
enteric arteries in SM-Bmal1–KO mice (Supplemental Figure 2, 
A–E). These data suggest that the effect of smooth-muscle BMAL1 
on contractile responses is not limited to mesenteric arteries.
In addition to responding to neuronal and humoral stimula-
tions, vascular smooth muscle in resistance arterioles contracts in 
response to mechanical stretch via a mechanism termed myogenic 
responses. To determine the role of smooth-muscle BMAL1 in myo-
genic responses in small resistance arteries that are more relevant to 
blood pressure, we investigated the myogenic responses in the fifth 
branch of mesenteric arteries (lumen diameters of 55 to 85 μm) iso-
lated from SM-Bmal1–KO mice and WT littermates at ZT5, a time 
point when a more pronounced difference in K+-, PE-, and 5-HT–
induced contraction was detected between the 2 mouse strains (Fig-
ure 2, A–E). As shown in Figure 3, A and B, in the presence of extra-
cellular Ca2+, when the vascular smooth muscle can generate active 
myogenic contraction, the vessel lumen diameter was increased 
to a larger extent in response to the pressure steps from 20 to 120 
mmHg in SM-Bmal1–KO mice than in WT control mice, indicating 
a compromised myogenic response in SM-Bmal1–KO mice. Con-
sistent with this result, when the average spontaneous tone at the 
physiological pressure of 60 mmHg was calculated as the percent-
age decrease in active lumen diameter from the passive diameter 
(23), vessels from SM-Bmal1–KO mice exhibited significantly less 
spontaneous tone than those in WT littermates (Figure 3B).
When the active myogenic response was eliminated in the 
absence of added Ca2+ and the presence of EGTA plus nitroprus-
side, the difference in vessel lumen increase between 2 strains of 
mice was largely diminished (Figure 3A; passive vs. active), indi-
cating that a compromised smooth-muscle myogenic response 
rather than a vascular structure change is largely responsible for 
the difference between SM-Bmal1–KO mice and WT controls. 
Nevertheless, it was noted that a small but significant (P < 0.05) 
difference remained in the absence of Ca2+ between the 2 strains 
of mice, suggesting that there is a moderate structural change in 
the fifth branch of mesenteric arteries from SM-Bmal1–KO mice. 
Consistent with this interpretation, there were trends toward a 
decrease in the cross-sectional lumen area and an increase in the 
cross-sectional wall area and, as a result, a small but significant 
increase in wall-to-lumen ratio (Supplemental Figure 3, A–D).
To further verify whether the vascular contractile differences 
detected in isolated vascular preparations are present in vivo, we 
determined the immediate pressor responses to i.v. injection of 
various doses of PE at ZT5 and ZT17. Similar to what we observed 
in isolated mesenteric arteries (Figure 2) and renal arteries (Sup-
plemental Figure 2) from WT littermates, the pressor responses 
to 10 or 50 μg/kg PE at ZT5 were significantly higher than those 
at ZT17, whereas such time-of-day difference was abolished in 
SM-Bmal1–KO mice. First, SM-Bmal1–KO mice exhibited a Cre-
mediated chromosome recombination that specifically deletes 
the Bmal1 gene in smooth-muscle–enriched tissues, such as the 
aorta, mesenteric artery, and bladder (Figure 1A). Second, Bmal1 
mRNA (Figure 1B) and protein (Figure 1C) were drastically 
decreased in mesenteric arteries from the SM-Bmal1–KO mice 
compared with those in WT littermates (Bmal1flox/flox mice). Third, 
the 24-hour mRNA oscillations of period circadian clock 1 (Per1) 
and period circadian clock 2 (Per2), 2 BMAL1 target genes, were 
abolished in mesenteric arteries by Bmal1 deletion (Figure 1, D 
and E). In addition, in agreement with the literature (19, 20), we 
also found that Cre recombinase was indeed expressed in heart 
but at a much lower level than in smooth muscle (Z. Guo and M. 
Gong, unpublished observations). In contrast to the drastic effect 
of Bmal1 deletion in the mesenteric artery, Bmal1 deletion in the 
heart had no effect on Per1 and Per2 mRNA 24-hour oscillation 
(Figure 1, F and G). Finally, PER2 oscillation was monitored in real 
time by measuring luminescence in mesenteric arteries or SCN-
containing brain slices isolated from SM-Bmal1–KO/mPer2Luc 
knockin mice. PER2 oscillations were completely lost in mesen-
teric arteries (Figure 1H), but remained normal in SCN-contain-
ing brain slices (Figure 1I).
In addition, we measured the body weight, body fat mass, 
fasting blood glucose, glucose tolerance, and insulin tolerance 
in SM-Bmal1–KO mice and WT littermates to determine whether 
the disruptions of adipogenesis and glucose metabolism reported 
in global Bmal1-KO mice (21) are present in the SM-Bmal1–KO 
mice. No difference was detected in any of these indices (Z. Guo 
and M. Gong, unpublished observations). We also measured 
kidney weight and length to determine whether the reduction 
of kidney mass in the absence of degenerative lesions reported 
in global Bmal1-KO mice (22) occurs in SM-Bmal1–KO mice. No 
difference was found between SM-Bmal1–KO mice and WT litter-
mates (Z. Guo and M. Gong, unpublished observations). Consis-
tent with those findings, we also did not find any significant differ-
ence in urine volume and blood sodium concentration between 
SM-Bmal1–KO mice and WT littermates (Z. Guo and M. Gong, 
unpublished observations).
Time-of-day variations in isolated vascular smooth-muscle contrac-
tion and in vivo pressor responses are suppressed in SM-Bmal1–KO mice. 
To investigate the role of smooth-muscle BMAL1 in vascular tone, 
superior mesenteric arteries were isolated from SM-Bmal1–KO mice 
and WT littermates at zeitgeber time 5 (ZT5) and ZT17. Endothelium 
was denuded, and their contractile responses to high potassium (K+), 
phenylephrine (PE), and serotonin (5-HT) were determined. Con-
sistent with our recent report in abdominal aorta (9), the contractile 
responses to all 3 stimuli in mesenteric arteries were higher at ZT5 
than at ZT17 in WT littermates (Figure 2, A–E). Strikingly, smooth-
muscle–specific Bmal1 deletion abolished the time-of-day variations 
in smooth-muscle contractile responses to K+ (Figure 2A), PE (Fig-
ure 2, B and C), and 5-HT (Figure 2, D and E). In addition, the maxi-
mal contractile responses to all 3 stimuli were markedly suppressed 
at both ZT5 and ZT17 in SM-Bmal1–KO mice compared with WT 
littermates (Figure 2, A, C, and E).
We next examined the effect of smooth-muscle BMAL1 on vas-
cular structure. We did not find significant differences in the medium 
thickness, medium area, lumen area, and ratio of medium to lumen 
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agonists were expected to drive the MLC20 phosphorylation to 
a higher level, thus providing a relatively larger window for the 
detection of a decrease in MLC20 phosphorylation in SM-Bmal1–KO 
mice. Two distinct methods, urea glycerol gel electrophoresis 
that separates un-, mono-, and diphosphorylated MLC20 (24) and 
Western blot using antibodies specific for phosphorylated MLC20 
(Thr18/Ser19), were used to determine MLC20 phosphorylation.
In WT littermates, stimulation of the vessels with PE plus 
5-HT significantly increased MLC20 phosphorylation at both ZT5 
(Figure 4, A–D, lanes 1 vs. 2) and ZT17 (Figure 4, A–D, lanes 5 vs. 
6), but the amplitude of MLC20 phosphorylation increase at ZT5 
was significantly higher than that at ZT17 (Figure 4, A–D, lanes 2 
vs. 6). These results correlate with the larger contractile responses 
at ZT5 relative to at ZT17 (Figure 2 and Supplemental Figure 2) and 
suggest that the time-of-day variation in contractile amplitude is 
mediated, at least in part, by MLC20 phosphorylation.
In SM-Bmal1–KO mice, stimulation of the vessels with PE plus 
5-HT also increased MLC20 phosphorylation at both ZT5 (Figure 4, 
A–D, lanes 3 vs. 4) and ZT17 (Figure 4, A–D, lanes 7 vs. 8). However, 
the amplitude of MLC20 phosphorylation increase in SM-Bmal1–
KO mice was selectively suppressed at ZT5 (Figure 4, A–D, lanes 2 
SM-Bmal1–KO mice (Figure 3C and Supplemental Table 1). In 
addition, the pressor responses to 10 or 50 μg/kg PE at ZT5 were 
smaller in SM-Bmal1–KO mice compared with those in WT litter-
mates (Figure 3C and Supplemental Table 1).
Taken together, these data demonstrate that smooth-muscle 
BMAL1 is essential for the 24-hour variations and normal ampli-
tude of contractile responses in vitro and in vivo.
MLC20 phosphorylation increase is selectively inhibited at ZT5 but 
not ZT17 in mesenteric arteries from SM-Bmal1–KO mice. Revers-
ible phosphorylation of the 20-kDa regulatory myosin light chain 
(MLC20) is a primary mechanism regulating smooth-muscle 
contraction (8); we therefore investigated the possibility that 
smooth-muscle BMAL1 may mediate the time-of-day variation of 
contraction through regulating MLC20 phosphorylation. Mesen-
teric arteries were isolated from SM-Bmal1–KO mice and WT lit-
termates at ZT5 or ZT17 and then incubated with PE and 5-HT to 
induce MLC20 phosphorylation. We used both PE and 5-HT rather 
than a single agonist to stimulate MLC20 phosphorylation to acti-
vate various branches of mesenteric arteries, as the contraction 
amplitude induced by PE or 5-HT varied at the different branches 
of mesenteric arteries (ref. 24 and Figure 2, B–E). Moreover, 2 
Figure 1. Characterization of SM-Bmal1–KO mice. (A) Analysis of smooth-muscle–specific Cre-mediated chromosome recombination by PCR using genomic 
DNA from SM-Bmal1–KO mice. MA, mesenteric artery; AG, adrenal gland; SM, skeletal muscle. (B) Real-time PCR analysis of Bmal1 mRNA expression in 
mesenteric arteries (n = 3–5). (C) Representative Western blots of BMAL1 and β-actin protein expression in mesenteric arteries (n = 8). (D–G) Real-time PCR 
analysis of Per1 (D and F) and Per2 (E and G) mRNA expression in mesenteric arteries (D and E) and the heart (F and G) (n = 3–5). ***P < 0.001 vs. KO at ZT11. 
(H and I) Representative LumiCycle luminescence recordings of PER2-luciferase protein oscillation in MA (H) and SCN-containing brain slice (I).
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tially bind to (Figure 5A). To determine whether BMAL1 binds to 
these putative E-boxes, we generated a rabbit polyclonal antibody 
that specifically recognized BMAL1 (Figure 5B) and performed a 
ChIP assay in mesenteric arteries isolated from WT mice at ZT5 
and ZT17. As a positive control, we examined whether BMAL1 
binds to the Per1 (a classic BMAL1 target) promoter and found that 
indeed it did, as expected (Figure 5C). Importantly, we found that 
BMAL1 bound to the Rock2 promoter at E-box 5 through E-box 8, 
but not at E-box 9 and E-box 10 (Figure 5, A and C). Moreover, 
more BMAL1 binding was detected at ZT17 than at ZT5, indicating 
that BMAL1 binds to the Rock2 promoter in a time-of-day–depen-
dent manner (Figure 5, C and D).
Second, to investigate whether the binding of BMAL1 to the 
Rock2 promoter regulates its activity, we cloned a 3.2-kb mouse 
Rock2 promoter, inserted it into a luciferase reporter vector (pGl3-
Rock2P-Luc), and transfected the pGl3-Rock2P-Luc vector into 
aortic vascular smooth-muscle cells (VSMCs) isolated from SM-
Bmal1–KO mice and WT littermates. In WT cells, the Rock2 pro-
moter exhibited a 14-fold increase in luciferase activity over the 
pGL3 luciferase vector (Figure 5E, column 1 vs. 2). In contrast, 
when transfected into Bmal1-deficient cells, Rock2 promoter activ-
ity was abolished (Figure 5E, column 2 vs. 4), suggesting that 
BMAL1 is required for Rock2 promoter activity in cultured VSMCs. 
Importantly, infection of Bmal1-deficient cells by BMAL1 adenovi-
rus almost completely restored Rock2 promoter activity in a con-
centration-dependent manner (Figure 5E, column 5 and 6 vs. 4).
Third, we investigated whether smooth-muscle Bmal1 dele-
tion affects Rock2 mRNA expression in vivo. Mesenteric arteries 
were isolated from SM-Bmal1–KO and WT littermates at ZT5 and 
vs. 4), but not at ZT17 (Figure 4, A–D, lanes 6 vs. 8), compared with 
that in WT littermates. As a consequence, the difference in the 
MLC20 phosphorylation between ZT5 and ZT17 was abolished in 
SM-Bmal1–KO mice, which correlates with the abolishment of the 
differences in contractile responses between ZT5 and ZT17 in SM-
Bmal1–KO mice (Figure 2 and Supplemental Figure 2).
Identification of ROCK2 as a new target of BMAL1 in mesenteric 
arteries. To identify molecular mechanisms that underlie agonist-
induced and BMAL1-mediated smooth-muscle contraction, we 
investigated several proteins that are either essential components 
of contractile apparatus or key regulators of MLC20 phosphoryla-
tion. By immunoblot analysis, we compared the expression levels 
of the following proteins at ZT5 in mesenteric arteries from SM-
Bmal1–KO and WT littermates: (a) α-SMA; (b) MLC20; (c) myosin 
phosphatase target subunit 1 (MYPT1); (d) 17-kDa PKC-poten-
tiated protein phosphatase-1 inhibitor (CPI-17); (e) Rho-kinase 
2 (ROCK2); and (f) small–molecular weight G protein RhoA. 
Interestingly, among all the proteins investigated, we found that 
ROCK2 was selectively decreased in SM-Bmal1–KO mice com-
pared with that in WT littermates (Supplemental Figure 4, A–G). 
Since ROCK2 is a key regulator of smooth-muscle contraction and 
blood pressure homeostasis and its dysfunction has been implicat-
ed in many cardiovascular diseases (25), we therefore tested the 
hypothesis that ROCK2 links BMAL1 and time-of-day variations 
in vascular smooth-muscle contraction by various approaches.
First, to determine whether BMAL1, as a transcriptional factor, 
directly binds Rock2 promoter, we analyzed the mouse Rock2 pro-
moter DNA sequence and identified multiple canonical E-boxes 
(CANNTG, where N can be any nucleotide) that BMAL1 can poten-
Figure 2. The time-of-day variation in agonist-induced contractile responses is suppressed in superior mesenteric artery from SM-Bmal1–KO mice. (A) 
The plateau response to 143 mM K+ (n = 4–8). (B and C) The concentration-response curve (B) and the maximum response (C) to PE (n = 6–9). **P < 0.01 vs. 
WT-ZT17 at 100 μM PE (D and E). The concentration-response curve (D) and the maximum response (E) to 5-HT (n = 6–9). *P < 0.05 vs. WT-ZT17 at 0.1 μM 
5-HT; ***P < 0.001 vs WT-ZT17 at 1 or 10 μM 5-HT.
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MYPT1 phosphorylation between ZT5 and 
ZT17 was abolished in SM-Bmal1–KO mice.
Finally, we investigated whether phar-
macological inhibition of ROCK2 suppresses 
vascular smooth-muscle contraction in a 
manner similar to that of genetic-deleting 
Bmal1. Endothelium-denuded superior mes-
enteric arteries were prepared from WT mice 
at ZT5 and ZT17 and then stimulated with 
5-HT in the presence of Rho kinase inhibi-
tor Y-27632 or vehicle (DMSO). The results 
demonstrate that Y-27632 suppressed 5-HT–
induced contractions at both ZT5 and ZT17 
(Figure 6D). Importantly, the extent of sup-
pression on the contraction was larger at ZT5 
than at ZT17; thus, the difference in 5-HT–
induced contraction between ZT5 and ZT17 
was abolished by Rho kinase blockade, which 
is similar to that in SM-Bmal1–KO mice (Fig-
ure 2 and Supplemental Figure 2).
Impairment of blood pressure circadian 
rhythm in SM-Bmal1–KO mice. To investigate 
whether smooth-muscle BMAL1 is involved 
in blood pressure circadian rhythm, we mea-
sured blood pressure of conscious, free-mov-
ing SM-Bmal1–KO mice and WT littermates 
using telemetry under 12:12 light/dark (L/D), 
constant dark (D/D), and constant light (L/L) 
conditions. Mean arterial pressure (MAP) 
was significantly decreased under all 3 condi-
tions in SM-Bmal1–KO mice compared with 
that in WT littermates (Figure 7A).
To investigate whether smooth-muscle 
BMAL1 is involved in the intrinsic blood pres-
sure circadian rhythm, we first determined 
blood pressure in the absence of the dominant external light cue 
under D/D conditions (26). Systolic blood pressure (SBP), dia-
stolic blood pressure (DBP), and pulse pressure were continuous-
ly measured for 7 consecutive days. As shown in Figure 7B, SM-
Bmal1–KO mice exhibited a decrease in SBP during the subjective 
dark phase without an apparent change during the subjective 
light phase. An analysis of the data using a nonlinear least-square 
fitting program, PHARMFIT (27), illustrated that the SBP circa-
dian oscillation amplitude was significantly decreased (Figure 
7C) and the acrophase (time of the peak) was significantly shifted 
forward (Figure 7D), but the period length (the time elapsed for 1 
complete oscillation) was unaltered (Figure 7E) in SM-Bmal1–KO 
mice relative to WT littermates.
A similar but more dramatic effect of smooth-muscle BMAL1 
on blood pressure circadian rhythm was also observed in DBP 
(Figure 7F). The pressure levels during both the subjective dark 
and light phases were decreased in the SM-Bmal1–KO mice, but 
the amplitude of decrease was bigger during the subjective dark 
phase than during the subjective light phase. Consequently, the 
amplitude of DBP oscillation was substantially decreased. The 
acrophase of DBP also shifted forward. Similar to SBP, the period 
length of the DBP was not different between the 2 strains of mouse.
ZT17, and Rock2 mRNA was quantified by real-time PCR. In WT 
vessels, Rock2 mRNA was significantly higher at ZT17 than that 
at ZT5 (Figure 6A). In BMAL1-deficient vessels, Rock2 mRNA 
expression was diminished at both ZT5 and ZT17, but the decrease 
was more dramatic at ZT17 than at ZT5 (Figure 6A). As a result, 
there was no difference in Rock2 mRNA between ZT5 and ZT17 in 
Bmal1-deficient mesenteric arteries.
Fourth, we investigated whether BMAL1 regulates the time-
of-day variations in ROCK2 activity. We determined the phos-
phorylation level of MYPT1 at Thr853 (an index of ROCK2 acti-
vation) in mesenteric arteries isolated from SM-Bmal1–KO mice 
and WT littermates at ZT5 and ZT17. In WT vessels, PE plus 5-HT 
significantly increased MYPT1 phosphorylation at ZT5 (Figure 6, 
B and C, lane 1 vs. 2) and ZT17 (Figure 6, B and C, lane 5 vs. 6). The 
amplitude of agonist-induced MYPT1 phosphorylation at ZT5 was 
significantly higher than that at ZT17 (Figure 6, B and C, lane 2 vs. 
6), which is consistent with larger contractile responses (Figure 2 
and Supplemental Figure 2) and MLC20 phosphorylation (Figure 
4) at ZT5 than at ZT17 in WT mice. In contrast, in SM-Bmal1–KO 
mice, agonist-induced MYPT1 phosphorylation was selectively 
reduced at ZT5 (Figure 6, B and C, lane 2 vs. 4), but not ZT17 (Fig-
ure 6, B and C, lane 6 vs. 8). Consequently, the difference in the 
Figure 3. Myogenic responses in isolated fifth branch of mesenteric arteries and diurnal pressor 
responses in vivo are suppressed in SM-Bmal1–KO mice. (A) Passive (in the absence of Ca2+) and 
active (in the presence of Ca2+) lumen diameter changes of the fifth branch of mesenteric arteries 
over intraluminal pressure from 20 to 120 mmHg. The data were calculated as the percentage of 
the passive lumen diameter at 60 mmHg. *P < 0.05; **P < 0.01 vs. WT-active at 60, 80, 100, and 
120 mmHg, respectively (n = 6–9). #P < 0.05; ##P < 0.01; ###P < 0.001 vs. WT-passive at 80, 100, and 
120 mmHg, respectively (n = 6–9). (B) Spontaneous tone was calculated as the percentage decrease 
in active lumen diameter from the passive diameter at 60 mmHg (n = 7–9). (C) Telemetric recording 
of pressor response to bolus PE injection at ZT5 or ZT17 in anesthetized mice (n = 3).
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The most striking effect of smooth-muscle BMAL1 on blood 
pressure circadian rhythm was seen in pulse pressure (Figure 7G). 
The level was significantly higher in the SM-Bmal1–KO mice than 
in the WT littermates due to a larger decrease in DBP than in SBP. 
In addition, JTK-cycle analysis (28) of the pulse pressure illustrat-
ed that the circadian oscillation of pulse pressure observed in WT 
littermates was abolished in SM-Bmal1–KO mice.
Neither the level nor the circadian oscillations of the locomo-
tor activity, however, were altered in the SM-Bmal1–KO mice com-
pared with WT littermates (Figure 7H). This result is consistent 
with the data showing that the Bmal1 gene remains intact in brain 
(Figure 1A) and that its target protein PER2 oscillation is normal 
(Figure 1I), indicating that the suppressed amplitude and shifted 
acrophase of blood pressure circadian oscillation in SM-Bmal1–KO 
mice are not due to changes in the SCN central pacemaker.
We also examined the effect of smooth-muscle BMAL1 on 
the heart rate (HR). Interestingly, smooth-muscle Bmal1 deletion 
decreased the HR during both the subjective dark and light phas-
es (Figure 7I), but had no effect on the HR circadian oscillation 
amplitude (Figure 7J), acrophase (Figure 7K), and period length 
(Figure 7L). These results are consistent with the data showing 
that Per1 and Per2 mRNA oscillation remains normal in the heart 
(Figure 1, F and G), indicating that the suppressed amplitude and 
shifted acrophase of blood pressure circadian oscillation in SM-
Bmal1–KO mice are unlikely to be attributed to changes in the HR.
To investigate whether the effect of smooth-muscle Bmal1 
deletion on blood pressure circadian rhythm is exacerbated by 
light, we then determined blood pressure for 7 consecutive days 
in the presence of L/L when the SCN central pacemaker was dis-
rupted (26). We found Bmal1 deletion in smooth muscle caused 
changes in BP (Supplemental Figure 5) very similar to those that 
occurred under D/D conditions, including a decrease in SBP, DBP, 
MAP, and HR (Supplemental Figure 5, A, E, F, and I), a decrease 
in the amplitude of SBP oscillation (Figure 7B) and no change in 
the acrophase and the period length of SBP oscillations (Figure 7, 
C and D), an increase in pulse pressure (Supplemental Figure 5G), 
and no effect on locomotor activity and HR circadian rhythm (Sup-
plemental Figure 5, H–L).
Interestingly, there were 2 changes in blood pressure circa-
dian rhythm observed in both SM-Bmal1–KO mice and WT litter-
mates under L/L conditions when compared with those under 
D/D conditions. First, under L/L conditions, only 1 single peak 
was observed in SBP, DBP, locomotor activity, and HR during 
the subjective dark phase (Supplemental Figure 5, A, E, F, H, and 
I), whereas under D/D conditions, 2 peaks were observed dur-
ing the subjective dark phase: one at the beginning and another 
at the end of the subjective dark phase (Figure 7, B, F, H, and I). 
Second, the period length of SBP oscillation was longer: 25.0 ± 
0.1 (L/L) vs. 24.0 ± 0.03 (D/D) hours (n = 12 each, P < 0.0001). 
The peak of the SBP, DBP, and MAP as well as locomotor activity 
Figure 4. The time-of-day variations in agonist-induced MLC20 phosphorylation are diminished in mesenteric arteries from SM-Bmal1–KO mice. (A and 
C) Representative urea/glycerol gel (A) and quantitative data (C; n = 7) of MLC20 phosphorylation induced by PE (100 μM) plus 5-HT (10 μM) for 2 minutes. 
Un-P MLC20, unphosphorylated MLC20; Mono-P MLC20, monophosphorylated MLC20; Di-P MLC20, diphosphorylated MLC20; MLC20-T, total MLC20, including 
un-, mono-, and diphosphorylated MLC20. (B and D) Representative Western blots (B) and quantitative data (D; n = 8) of MLC20 phosphorylation induced by 
PE plus 5-HT using the antibodies specific for phosphorylated MLC20 (Thr18 and Ser19) and total MLC20 protein.
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and HR during the subjective dark phase shifted gradually from 
in the middle of the subjective dark phase to the end of the sub-
jective dark phase over the 7-day period (Supplemental Figure 5, 
A, E, F, H, and I).
We also determined the blood pressure oscillation under 12:12 
L/D conditions to investigate whether the external light cue was 
able to correct the compromised blood pressure circadian oscilla-
tion in the SM-Bmal1–KO mice. As shown in Supplemental Figure 
6, A–L, changes observed in SBP, DBP, pulse pressure, locomotor 
activity, and HR were very similar under D/D and L/L conditions, 
indicating that light, a principal entraining signal to the SCN, 
has little effect on impaired blood pressure circadian rhythm by 
smooth-muscle Bmal1 deletion.
To ensure that the observed blood pressure alterations in SM-
Bmal1–KO mice resulted from smooth-muscle Bmal1 deletion, but 
not Cre recombinase expression, we measured blood pressure in 
the SM22α-Cre mice under 12:12 L/D conditions. No differences in 
either blood pressure level or circadian oscillations were observed 
between the age- and sex-matched SM22α-Cre mice and Bmal1flox/flox 
mice (Supplemental Figure 7A).
A moderate Bmal1 dele-
tion was seen in the heart 
in SM-Bmal1–KO mice (Z. 
Guo and M. Gong, unpub-
lished observations), which 
is consistent with a moder-
ate decrease in the HR in 
SM-Bmal1–KO mice (Figure 
7I, Supplemental Figure 
5I, and Supplemental Fig-
ure 6I). To ensure that the 
observed blood pressure 
alterations in SM-Bmal1–
KO mice resulted from 
smooth-muscle Bmal1 dele-
tion but not cardiomyocyte 
Bmal1 deletion, we mea-
sured blood pressure in an 
inducible cardiomyocyte-
specific Bmal1-knockout 
mouse model (iCS-Bmal1–
KO), which was generated 
by crossing Bmal1flox/flox mice 
(18) with cardiac-specific 
MerCreMer recombinase 
mice (29), as we previously 
reported (30). As shown in 
Supplemental Figure 7B, 
under 12:12 L/D conditions, 
neither the MAP level nor 
the circadian oscillations of 
the MAP were altered in the 
iCS-Bmal1–KO mice com-
pared with those in iCS-
Bmal1–WT mice.
To test the possibil-
ity that the loss of smooth-
muscle tone in SM-Bmal1–KO mice may have an effect on the 
baroreflex function, thus contributing to the loss of blood pressure 
circadian rhythm, we determined the spontaneous baroreflex sen-
sitivity across the 24-hour day under 12:12 L/D conditions in con-
scious and free-moving SM-Bmal1–KO mice and WT littermates 
using the sequence method (31). Consistent with the previous 
reports in humans (31, 32), the spontaneous baroreflex sensitivity 
in WT littermates exhibited time-of-day variations with a higher 
sensitivity during the resting phase (the light phase in mice) than 
during the active phase (the dark phase in mice; Supplemental 
Figure 8). In contrast, the spontaneous baroreflex sensitivity in 
SM-Bmal1–KO mice was diminished across a 24-hour period, with 
a more pronounced decrease during the light phase. Importantly, 
the difference in spontaneous baroreflex sensitivity between light 
and dark phases was abolished in the SM-Bmal1–KO mice.
In summary, selective deletion of Bmal1 from smooth muscle 
but not from cardiomyocyte decreased the 24-hour MAP. In par-
ticular, deletion of Bmal1 from smooth muscle compromised blood 
pressure circadian rhythm without affecting locomotor activity. In 
addition, deletion of Bmal1 from smooth muscle altered 2 of the 3 
Figure 5. BMAL1 binds to Rock2 promoter in mesenteric arteries and is required for Rock2 promoter activity in 
cultured VSMCs. (A) Schematic diagram of a 3.5-kb mouse Rock2 promoter showing the positions of putative E-boxes 
(E) 1 to 10 and ChIP PCR primers relative to the translational start site (TSS). ChIP-F, forward primers; ChIP-R, reverse 
primers. (B) Characterization of the BMAL1 antibody by Western blots using cell lysate from Bmal1-deficient (KO) and 
WT mouse aortic VSMCs (mVSMC) as well as human embryonic kidney 293 cells (HEK293), transfected with a pSport6 
control vector (Ctrl) or a pSport6 vector expressing human BMAL1 (hBMAL1). (C and D) Representative ChIP-PCR (C) 
and quantitative data (D; n = 4) show that BMAL1 binds to the Per1 promoter and the Rock2 promoter at E-boxes 5 to 
8, but not E-boxes 9 to 10, in a time-of-day–dependent manner. (E) Restoration of Rock2 promoter activity by BMAL1 
adenovirus–mediated gene expression in Bmal1-deficient mVSMCs (+, low dose; ++, high dose; n = 3–6).
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increase, and in in vivo pressor responses in anesthetized mice; 
(b) the inhibition of agonist-induced vasoconstriction was associ-
ated with suppression of MLC20 phosphorylation, Rock2 mRNA, 
and activity; moreover, BMAL1 directly bound to Rock2 promoter 
in a time-of-day–dependent manner in mesenteric arteries and 
was required for Rock2 promoter activity in cultured VSMCs; (c) in 
mice lacking smooth-muscle Bmal1, the blood pressure level was 
decreased; blood pressure circadian oscillation amplitude was 
decreased, whereas light-induced blood pressure changes were 
not affected; acrophase was forward shifted, but the period length 
and light-induced changes remained unaltered; and (d) smooth-
muscle–specific deletion of Bmal1 markedly elevated pulse pres-
sure level and abolished pulse pressure circadian rhythm.
How do our findings contribute to the current understanding 
of blood pressure circadian rhythm? It was long believed that all 
circadian rhythms, including blood pressure circadian rhythm, 
were primarily generated and controlled by the central pacemaker 
SCN. Indeed, ablation of the SCN results in the loss of circadian 
oscillation of blood pressure, along with the loss of endocrine and 
behavioral rhythms (33). However, recent studies illustrate that 
the behavioral circadian rhythm that is mainly controlled by the 
SCN does not correlate precisely with the blood pressure circadi-
an rhythm in a 24-hour period (6, 34), indicating an involvement 
of additional mechanisms in the generation and maintenance of 
blood pressure circadian rhythm. This concept is supported by the 
discovery that each of the core clock genes present in the SCN are 
also expressed and function in peripheral tissues (4–7). However, 
which clock gene in which peripheral tissue or tissues contributes 
to the blood pressure circadian rhythm remains elusive.
The results of the current study demonstrated that smooth-
muscle BMAL1 substantially contributes to the maintenance of 
major characteristics of the blood pressure oscillation: it decreased 
the oscillation amplitude and forward shifted the acrophase with-
out affecting the period length. Moreover, deletion of Bmal1 from 
smooth muscle markedly elevated pulse pressure level, abolished 
pulse pressure circadian rhythm, and diminished the difference 
between the light and dark phases in baroreflex sensitivity.
Lack of Bmal1 in smooth muscle does not affect light condition–
induced change in blood pressure circadian oscillation. As shown in 
Figure 8A, in the WT littermates, the blood pressure oscillation 
amplitude gradually decreased from L/D to D/D and to L/L con-
ditions. In contrast, the acrophase (Figure 8B) and period length 
(Figure 8C) of the blood pressure circadian oscillation remained 
constant under L/D and D/D conditions, but significantly 
increased under L/L conditions. Interestingly, deletion of Bmal1 
from smooth muscle significantly suppressed the blood pressure 
circadian oscillation amplitude and forward shifted the acrophase 
(Figure 7 and Supplemental Figures 5 and 6), but it had no detect-
able effect on L/L-induced changes in blood pressure circadian 
oscillations, including suppression in oscillation amplitude (Fig-
ure 8A), delay in acrophase (Figure 8B), and increase in oscilla-
tion period length (Figure 8C) as well as L/L-induced changes in 
locomotor activity (Figure 8D). This indicates a minimal role of 
vascular smooth-muscle BMAL1 and contractility in light condi-
tion–induced alterations in blood pressure circadian oscillation.
Discussion
Major findings of the current study are as follows: (a) smooth-mus-
cle–specific deletion of Bmal1 did not affect the central pacemaker 
SCN, but drastically suppressed the amplitude and the time-of-day 
variations in vasoconstriction in isolated preparations in response 
to various agonist stimulations, in myogenic response to pressure 
Figure 6. The time-of-day 
variation of Rock2 mRNA 
expression and ROCK2 
kinase activity is regulated 
by BMAL1 and is involved in 
the time-of-day variation of 
smooth-muscle contraction. 
(A) Real-time PCR analysis of 
Rock2 mRNA expression in 
mesenteric arteries (n = 3–5). (B 
and C) Representative Western 
blots (B) and quantitative data 
(C; n = 7–8) of total MYPT1 
(T-MYPT1) and phosphorylated 
MYPT1 at Thr853 (p-MYPT1853) 
in mesenteric arteries. (D) 
Concentration-response curve 
showing that the time-of-day 
variation in vasoconstriction 
induced by 5-HT was dimin-
ished by pretreatment of mes-
enteric arteries with Rho-kinase 
inhibitor Y27632 (10 μM, 30 min; 
n = 7–8). Veh, vehicle (DMSO). 
*P < 0.05 vs. ZT17 + vehicle at 
10 μM 5-HT.
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elusive, multiple population-based cohort studies (35–37) and ran-
domized trials of hypertension treatment (38) have shown that 
increased pulse pressure is associated with a variety of adverse 
cardiovascular outcomes, and there are reports that ambulatory 
monitoring of pulse pressure substantially refines the risk strati-
fication in hypertensive patients (39, 40). Thus, our finding that 
smooth-muscle BMAL1 regulates the level and circadian rhythms 
of blood pressure including pulse pressure may have an important 
implication for human health.
How does smooth-muscle BMAL1 regulate blood pressure 
circadian rhythm? We and others have reported that vascular 
smooth-muscle contractile responses to various agonists exhibit 
a time-of-day variation (9–14). Therefore, one potential mecha-
nism is that smooth-muscle BMAL1 regulates the time-of-day 
variation of vasoconstriction and thereby participates in the reg-
ulation of blood pressure circadian rhythm. Several lines of evi-
dence from the current study support this potential mechanism. 
normal blood pressure levels as well as blood pressure circadian 
rhythm. The MAP decreased by about 9 to 10 mmHg in the global 
BMAL1-knockout mice (16). In mice lacking smooth-muscle Bmal1, 
an approximately 7 mmHg blood pressure decrease was observed 
(Figure 7A), whereas in mice lacking cardiomyocyte Bmal1, no 
difference in blood pressure levels was observed (Supplemental 
Figure 7B), suggesting a major contribution of the smooth-muscle 
BMAL1 to the overall blood pressure level decrease in the global 
Bmal1-knockout mice. Moreover, blood pressure circadian rhythm 
amplitude and acrophase were significantly altered in mice lack-
ing smooth-muscle Bmal1 under D/D (Figure 7, B–G), L/L (Supple-
mental Figure 5), and 12:12 L/D conditions (Supplemental Figure 
6). A more striking effect of deleting smooth-muscle Bmal1 on 
blood pressure was observed in pulse pressure, with a dramatic 
increase in pulse pressure level and a complete loss of pulse pres-
sure circadian rhythm (Figure 7G and Supplemental Figure 5G). 
While the significance of pulse pressure circadian rhythm remains 
Figure 7. Circadian rhythms in blood pressure, but not in locomotor activity and HR, are altered in SM-Bmal1–KO mice under D/D conditions. (A) 
24-hour MAP under 12:12 L/D, D/D, and L/L conditions (n = 5–8). (B and F–I) 7-day SBP (B), DBP (F), pulse pressure (G), locomotor activity (H), and HR (I) 
under D/D conditions (n = 5–7). (C–E) SBP circadian oscillations in amplitude (C), acrophase (D), and period length (E). (J–L) HR circadian oscillations in 
amplitude (J), acrophase (K), and period length (L).
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and tension measurement because we (Figure 3C) and others 
(46) have demonstrated a similar “antiphase” temporal relation-
ship between the in vivo PE-induced pressor response and blood 
pressure. This paradoxical observation suggests the relationship 
between the time-of-day vasoconstriction variation and blood 
pressure circadian rhythm is complex rather than linear. This is 
not entirely unexpected, since vasoconstriction-induced blood 
pressure change will trigger sympathetic, endocrine, and local 
environmental changes via multiple mechanisms. Indeed, we 
(Supplemental Figure 8) and others (31, 32) have demonstrated 
that the spontaneous baroreflex sensitivity showed time-of-day 
variations, which is in phase with the time-of-day vasoconstric-
tion variation (Supplemental Figure 8 vs. Figure 2).
The molecular mechanism underlying the time-of-day varia-
tion in vascular smooth-muscle contraction remained completely 
unknown until Saito et al. recently reported that, in cultured cells 
and isolated aorta, the expression and activity of ROCK2 exhib-
ited a circadian rhythm in phase with that of MLC20 phosphoryla-
tion (47). The current study demonstrates for the first time, to our 
knowledge, that, in isolated mesenteric arteries, BMAL1 directly 
binds to the E-box–containing region in the Rock2 promoter in a 
time-of-day–dependent manner (Figure 5, C and D), which is in 
phase with Rock2 mRNA expression (Figure 6A). A pivotal role of 
smooth-muscle BMAL1 in Rock2 transcriptional regulation was 
further demonstrated by complete loss of Rock2 promoter activ-
ity in Bmal1-deficient VSMCs and by the complete restoration of 
Rock2 promoter activity by restoring BMAL1 expression using ade-
novirus-mediated gene transfer (Figure 5E). Moreover, a temporal 
First, the time-of-day variation in contractile responses to high 
K+ depolarization and agonist (PE and 5-HT) stimulation was 
abolished in smooth-muscle Bmal1-deficient and endothelium-
denuded superior mesenteric arteries (Figure 2) and renal arter-
ies (Supplemental Figure 2). We denuded endothelium, as we 
have usually done in our experiments (9, 41–44), to focus on 
studying smooth-muscle function, as a recent report demonstrat-
ed that selective deletion of a gene from smooth muscle affected 
endothelium function (45). Second, the myogenic responses were 
attenuated in the fifth branch of mesenteric arteries from SM-
Bmal1–KO mice compared with that from WT littermates (Figure 
3, A and B). Surprisingly, a moderate inward eutrophic vascular 
remodeling was found in the fifth branch of mesenteric arteries 
(Supplemental Figure 3), but not in the second branch of mesen-
teric arteries (Supplemental Figure 1). Such selective and moder-
ate vascular remodeling may be a direct effect of smooth-muscle 
Bmal1 deletion or a compensatory response to a decrease in blood 
pressure. Further studies are required to clarify this issue. Third, 
in line with these ex vivo vasoconstriction studies, the time-of-
day variation in pressor response to PE was also diminished in 
anesthetized SM-Bmal1–KO mice (Figure 3C). Fourth, the time-
of-day variation in MLC20 phosphorylation induced by agonist 
was attenuated in smooth-muscle Bmal1-deficient mesenteric 
arteries (Figure 4). However, one surprising finding of the cur-
rent study is that the phase of vasoconstriction does not correlate 
with the phase of blood pressure level in WT littermates (Figure 
2 vs. Figure 7, B, F, and G). This finding is unlikely to be attrib-
utable to the time delay caused by the ex vivo tissue preparation 
Figure 8. The change in blood pressure circadian rhythm with light is not altered in SM-Bmal1 mice. (A–C) The amplitude (A), acrophase (B), and period 
length (C) of the rhythmicity were calculated from SBP data collected under 12:12 L/D, D/D, and L/L conditions (n = 8). (D) 12-hour means of locomotor 
activity under L/D, D/D, and L/L conditions (n = 8). “L”, subjective light condition. “D”, subjective dark condition.
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Assessment of mesenteric myogenic tone. The fifth branches of mes-
enteric arteries with an inner diameter of 55 to 85 μm were prepared 
from SM-Bmal1–KO mice and WT littermates and then cannulated in 
a pressure myograph system (Living Systems Instrumentation). An 
active and passive pressure-diameter curve was recorded in the pres-
ence of Ca2+ and the absence of Ca2+ plus EGTA and nitroprusside, 
respectively, by 20 mmHg stepwise increase of intraluminal pressure 
from 0 to 120 mmHg in a physiological buffer at 37°C gassed with a 
95% O2–5% CO2 gas mixture as described (24).
Analysis of MLC20 phosphorylation. Mesenteric arteries were iso-
lated from SM-Bmal1–KO mice and WT littermates at ZT5 or ZT17. 
After equilibration in normal Krebs-Ringer bicarbonate buffer at 37°C 
for 30 minutes, mesenteric arteries were stimulated with 5-HT (10 
μM) plus PE (100 μM) for 2 minutes, followed by immediate freez-
ing in liquid nitrogen–chilled acetone containing 10% trichloroacetic 
acid. MLC20 phosphorylation was then determined by urea/glycerol-
PAGE as described (24) and by immunoblots using a MLC20 phosphor-
ylation-specific antibody (Thr18/Ser19; Cell Signaling Technology) as 
described (49, 51–53).
BMAL1 ChIP assay. A custom ChIP-grade BMAL1 rabbit polyclonal 
antibody was produced by Genemed Synthesis against mouse BMAL1 
amino acids 59–66 (TDKDDPHGRLEYAEHQGR). BMAL1 antibody 
was purified from antisera by immunoaffinity chromatography using 
the antigen peptide coupled to agarose beads as described (49).
Mesenteric arteries were isolated from Bmal1flox/flox mice at ZT5 
and ZT17. Mesenteric arteries were fixed with 1% formaldehyde for 15 
minutes to preserve the protein-DNA interactions. Mesenteric arteries 
were lysed in an SDS buffer containing protease inhibitors, and chro-
matin was fragmented by sonication. Three mesenteric arteries were 
pooled as 1 sample for BMAL1 ChIP analysis. The diluted chromatin 
was precleared by incubating with salmon sperm DNA (Life Technolo-
gies) and protein A/G agarose beads (Santa Cruz Biotechnology Inc.) 
and subjected to immunoprecipitation by incubating with the BMAL1 
antibody (2 μg) or an equal amount of nonspecific rabbit IgG (Vector 
Laboratory). The immune complexes were pulled down by protein 
A/G agarose beads and eluted. The crosslinks between protein and 
DNA were reversed by heating at 65°C for 4 hours. The released DNA 
was purified and amplified by PCR. The primers for mouse Per1, mouse 
Rock2 E-boxes 5 to 8, and mouse Rock2 E-boxes 9 to 10 are described 
in Supplemental Table 2.
Cloning mouse Rock2 promoter. A mouse bacterial artificial chro-
mosome clone containing the mouse Rock2 promoter was purchased 
from Life Technologies. An approximately 3.2-kb PCR product 
(–2,402 to +807 bp, relative to the translational initiation site) was 
amplified by PCR using primers as described in Supplemental Table 
2, verified by DNA sequencing (Z. Guo and M. Gong, unpublished 
observations), and subcloned into the pGL3 basic vector (Promega) 
at the XhoI and KpnI sites.
ROCK2 promoter assay. Bmal1-deficient and WT VSMCs were iso-
lated from SM-Bmal1–KO and WT littermate aortas as described (49, 
54, 55). Cells were cotransfected with pGl3-Rock2 luciferase vector and 
a Renilla luciferase using Lipofectamine-Plus Reagent (Life Technolo-
gies). A human BMAL1 adenovirus was purchased from Vector BioLabs 
and was purified by CsCl density gradient centrifugation as described 
(42). BMAL1 adenoviral expression in VSMC was verified by Western 
blot (Z. Guo and M. Gong, data not shown). Rock2 promoter activity was 
assayed by a modified dual luciferase enzyme assay as described (55).
correlation of ROCK2 function (pMYPT1853 phosphorylation) with 
vasoconstriction (Figure 6, B and C, vs. Figure 2) and MLC20 phos-
phorylation (Figure 6, B and C, vs. Figure 4) was observed in WT 
mice, but lost in SM-Bmal1–KO mice.
In summary, the current study provides several lines of evi-
dence indicating that smooth-muscle BMAL1 is critical for time-
of-day–dependent vasoconstriction and thereby blood pressure 
circadian rhythm. Moreover, the current study also reveals a 
mechanism by which smooth-muscle BMAL1 regulates MLC20 
phosphorylation and vasoconstriction via ROCK2 in a time-of-
day–dependent manner. Since disruption of blood pressure cir-
cadian rhythm is implicated in many human diseases, includ-
ing hypertension, acute myocardial infarction, sudden cardiac 
death, and stroke and is emerging as an index for future target 
organ damage and cardiovascular outcomes (2, 3), the new 
mechanistic insights into the daily control of vasoconstriction 
and blood pressure obtained in the current study could contrib-
ute to the foundation for future elucidation of the pathogenesis 
of many cardiovascular diseases involving disruption of blood 
pressure circadian rhythm.
Methods
Animals. SM-Bmal1–KO mice and iCS-Bmal1–KO mice were gener-
ated by crossing Bmal1flox/flox mice (18) with smooth-muscle–spe-
cific SM22α-Cre knockin mice (19) and cardiac-specific MerCreMer 
recombinase mice (30), respectively. SM-Bmal1–KO/Per2Luc mice 
were generated by crossing SM-Bmal1–KO mice with mPer2Luc knock-
in mice (48). Bmal1flox/flox mice, SM22α-Cre knockin mice, cardiac-spe-
cific MerCreMer recombinase mice, and mPer2Luc knockin mice were 
purchased from the Jackson Laboratory. Only male mice at 12 to 16 
weeks of age were used, and the mice were kept on a 12:12 L/D cycle 
unless indicated otherwise.
Analysis of smooth-muscle–specific Cre-mediated chromosome 
recombination in SM-Bmal1–KO mice. Genomic DNAs were extracted 
from various tissues of SM-Bmal1–KO mice and subjected to PCR 
analysis using a combination of 3 primers that were able to simulta-
neously detect both Bmal1-KO and WT (Bmal1flox/flox) gene products 
as described (18).
Quantitative analysis of mRNA expression. Mesenteric arteries were 
isolated from SM-Bmal1–KO mice and WT littermates at ZT5, ZT11, 
ZT17, and ZT23 (ZT0, light on; ZT12, light off). RNA extraction, cDNA 
synthesis, and real-time PCR were carried out as described (41, 49). 
The real-time PCR primers for mouse Per1 and Per2 were the same as 
those previously described (9). The real-time PCR primers for mouse 
Rock2 are described in Supplemental Table 2.
Real-time luminescence analysis of Per2 gene expression. Mesenteric 
arteries and coronal brain sections containing SCN were isolated from 
SM-Bmal1–KO/Per2Luc mice and Per2Luc knockin mice at ZT10 to ZT11 
and were then cultured in 35-mm Petri dishes at 36°C in a light-tight, 
water-jacketed incubator. Luminescence was continuously recorded 
by LumiCycle (Actimetrics) as described (48).
Isometric tension measurement. Mesenteric arteries and right renal 
arteries were isolated from SM-Bmal1–KO mice and WT littermates at 
ZT5 or ZT17. Superior mesenteric arteries and renal arteries were cut 
into small spiral strips (about 3 mm in length and 350 μm in width). 
Endothelium was denuded, and isometric contractions were mea-
sured as described (9, 41–44, 50).
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Study approval. All animal procedures were approved by the Institu-
tional Animal Care and Use Committee of the University of Kentucky.
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Telemetric measurement of blood pressure circadian rhythm and 
diurnal pressor responses. SM-Bmal1–KO mice and WT littermates were 
chronically instrumented in the left common carotid artery with a 
telemetry probe as described (27). After 10 days of recovery, SBP, DBP, 
MAP, pulse pressure, HR, and locomotor activity data were collected 
for 3 consecutive days on a 12:12 L/D cycle, 7 consecutive days under 
D/D conditions, and 7 consecutive days under L/L conditions, respec-
tively. Diurnal pressor responses to PE were measured in anesthetized 
mice either at ZT5 or ZT17 as described (9).
Statistics. All data were expressed as mean ± SEM. For compari-
son of 1 parameter between 2 strains of mice, statistical analysis was 
performed using 2-tailed, unpaired Student’s t test. For comparison 
of multiple parameters between 2 strains of mice at a single time 
point, statistical analysis was performed using 1-way ANOVA with 
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